Fabio Chianelli
​Chairman and Chief Executive Officer

Mr. Chianelli has over 15 years of experience with specialty life sciences companies. He was the Founder and President of Revive Therapeutics Ltd. (CSE: RVV) between 2012 and 2019. From January 2000 to January 2012, Mr. Chianelli held senior roles in investor relations, business development, and marketing and sales with Generex Biotechnology Corporation.  Mr. Chianelli received his Bachelor of Commerce from Ryerson University.

Carmelo Marrelli
​Chief Financial Officer

Mr. Marrelli holds a Bachelor of Commerce degree from the University of Toronto and is qualified as a Chartered Accountant and as a Certified General Accountant in Canada. Mr. Marrelli has been a principal of Marrelli Support Services Inc., a firm providing administration services to Canadian public companies, since February 2009 and, prior to February 2009, a partner with Marrelli & Drake Corporate Services (formerly Duguay & Ringler Corporate Services) (a firm providing administration services to Canadian public companies). Mr. Marrelli also serves as the Chief Financial Officer of several publicly-listed junior mining companies and as a director of Odyssey Resources Limited, an Exchange listed issuer.

Dr. Owen Van Cauwenberghe, PhD
​Research and Development

An established leader and innovator with over 19 years of experience in the pharmaceutical and biotechnology sectors with a wide range of industry expertise in brand and generic strategic definition, organizational design, product / analytical / formulation development, project management, product innovation and commercialization.​   Founding Partner, President and COO of Bio Therapeutic Molecules Inc., Adjunct Associate Professor in the Waterloo School of Pharmacy, President and Board Member at MedC Biopharma, Expert Advisory Board Member at MMGenetics, former Chief Research Officer at AgMedica Bioscience Inc., former Director at Accucaps Industries Ltd. and former Principal Research Scientist and Director at Eli Lilly Canada.

Dr. Joga Gobburu, PhD, MBA
​Clinical and Regulatory Advisor

Dr. Gobburu is a world-renowned scientific leader in the area of quantitative disease models and their applications to decisions. He is best known for transforming the field of pharmacometrics into a decision-supporting science. His experience as a senior biomedical research scientist and Director of Pharmacometrics at the Food and Drug Administration (FDA) gives him unique insight into the technical, regulatory, and decision-making aspects in all phases of drug development. He obtained his BPharm and MSc in chemistry from the Birla Institute of Technology and Science, his PhD in pharmaceutical sciences from North Dakota State University, and his MBA from Johns Hopkins University.

Dr. Maurizio Fava, MD

Dr. Fava is a world leader in the field of depression. He has edited eight books and authored or co-authored more than 900 original articles published in medical journals with international circulation, articles which have been cited more than 85,000 times in the literature and with an h index of over 140. Dr. Fava founded and was director of the Massachusetts General Hospital (MGH) Depression Clinical and Research Program from 1990 until 2014. Under Dr. Fava’s direction, the Depression Clinical and Research Program became one of the most highly regarded depression programs in the country, a model for academic programs that link, in a bi-directional fashion, clinical and research work. In 2007, he also founded and is now the executive director of the MGH Psychiatry Clinical Trials Network and Institute, the first academic CRO specialized in the coordination of multi-center clinical trials in psychiatry. Dr. Fava has been successful in obtaining funding as principal or co-principal investigator from both the National Institutes of Health and other sources for a total of more than $120 million. Dr. Fava’s prominence in the field is reflected in his role as the co-principal investigator of STAR*D, the largest research study ever conducted in the area of depression, and of the RAPID Network, the NIMH-funded series of studies of novel, rapidly-acting antidepressant therapies. Dr. Fava has also developed with Dr. David Schoenfeld a novel design (with over five patents), the sequential parallel comparison design (SPCD), to address the problem of excessive placebo response in drug trials and to markedly reduce sample size requirements for these trials. He is also the former President of the American Society of Clinical Psychopharmacology.

Dr. Robert Hauser, MD, MBA
​Scientific and Clinical Advisor (Parkinson's disease)

Dr. Robert Hauser is Professor of Neurology at the University of South Florida College of Medicine, in Tampa, Florida. He serves as Director of the USF Parkinson's Disease and Movement Disorders Center, a Parkinson Foundation Center of Excellence. Dr. Hauser earned a medical degree from Temple University School of Medicine, in Philadelphia, Pennsylvania, and completed neurology training at the Eastern Virginia Graduate School of Medicine, in Norfolk, Virginia. Dr. Hauser completed a fellowship in Movement Disorders at the University of South Florida and became Center Director in 1994. Dr. Hauser has authored or co-authored more than 300 peer-reviewed publications and is one of the world's most cited Parkinson's Disease investigators. He is Past Chairman of the Interventional Neurology Section of the American Academy of Neurology, has served on the executive committee of the Parkinson Study Group, and was a member of the steering committee for the NIH sponsored Neuroprotective Exploratory Trials in Parkinson's Disease program (NET-PD). Dr. Hauser lectures frequently at scientific meetings and served as Chairman of the 2009 World Federation of Neurology International Congress on Parkinson's Disease and Related Disorders. He has extensive expertise in clinical trial design and execution. Outcome measures that he developed have become the gold standard for use in clinical trials.

Dr. Alberto Espay, MD
Scientific and Clinical Advisor (Parkinson's disease)

Dr. Alberto Espay, MD, is professor and endowed chair of the University of Cincinnati James J. and Joan A. Gardner Family Center for Parkinson’s Disease and Movement Disorders. He trained in neurology at Indiana University as well as in clinical and electrophysiology of movement disorders at the University of Toronto, where he obtained a master’s degree in clinical epidemiology and healthcare research. A prolific researcher and author, Dr. Espay has published more than 250 peer-reviewed research articles, 25 book chapters and seven books. His most recent is the first targeting the general public, Brain Fables.  Dr. Espay has served as chair of the Movement Disorders Section of the American Academy of Neurology; associate editor of Movement Disorders, the official journal of the International Parkinson and Movement Disorder Society (MDS); and in the executive committee of the Parkinson Study Group. He currently serves as chair of MDS Technology Task Force and as secretary of the Pan-American Section of the MDS. Dr. Espay is also an honorary member of the Mexican Academy of Neurology.